Safety, Tolerability, and Pharmacokinetics of THN391 in Early Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Phase 1b Study

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of multiple ascending doses of THN391 in subjects with early **Alzheimer's Disease**. This is clinically relevant as it aims to determine the appropriate dosage and potential adverse effects of THN391, which could contribute to the development of new therapeutic strategies for managing Alzheimer's Disease. The study is designed as a double-blind, randomized, placebo-controlled, Phase 1b trial, ensuring rigorous assessment of the investigational product's effects in the target population.

The clinical trial involves a total of **20 participants** diagnosed with **Alzheimer's Disease**. The study population includes both male and female subjects, with an age range categorized as **4**, which typically corresponds to adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, and there are no specific lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the principal inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **double-blind**, **randomized**, **placebo-controlled** study to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of THN391 in subjects with early **Alzheimer's Disease**. The trial is categorized as a Phase 1b study and is expected to commence recruitment on March 24, 2025, with an estimated completion date of April 30, 2026. The study will involve a series of visits, beginning with an inclusion visit where participants will be screened for eligibility based on predefined criteria. This initial visit will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will undergo a series of follow-up visits at regular intervals. These visits are designed to monitor the participants' health, assess the safety and tolerability of the investigational product, and collect pharmacokinetic data. The sequence and frequency of these visits will be determined by the study protocol, ensuring comprehensive data collection and participant safety. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the intervention.

Participant involvement in the study is expected to last until the end-of-study visit, unless specific conditions necessitate early termination. Such conditions may include adverse events, withdrawal of consent, or any other protocol-defined criteria that compromise participant safety or data integrity. The trial's design and procedures are structured to maintain scientific rigor while prioritizing participant well-being throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on March 24, 2025, with an estimated completion date of April 30, 2026. The efficacy assessment will be conducted in accordance with the trial's objectives and endpoints, although specific primary and secondary endpoints are not detailed in the available data. The trial will adhere to rigorous standards typical of Phase 3 studies, ensuring that efficacy is evaluated through appropriate methodologies and timepoints. The trial's design will likely incorporate validated scales, laboratory tests, or patient-reported outcomes to measure efficacy, consistent with standard practices in clinical research. The absence of specific endpoints in the provided data suggests that these will be defined in the detailed trial protocol, ensuring a comprehensive evaluation of the investigational product's efficacy.